News

More than 1000 patients were recruited from around the world to participate in the study, which was conducted by Merck KGaA, ImClone Systems’ Erbitux partner outside of North

The proposed transaction remains subject to other customary closing conditions, including approval of the transaction by Conor Medsystems' stockholders. The companies hope to close the $1.4 billion transaction

C. Nicholas Hodge, Amphora's CSO and founder, said: “We are delighted that Genentech sees the potential value of one of our early stage programs. I personally see this

Under the terms of the agreement, AVI is granting Eleos an exclusive license to AVI's Neugene third-generation antisense chemistry to treat cancer with p53-related drugs. In return, Eleos

Squamous cell carcinoma SCC of the head and neck continues to be a clinical challenge. Even with the use of modern therapeutic options, 50% of all patients will

RNA interference, or RNAi, is an emerging field of biotechnology that involves blocking production of disease causing proteins. The studies will utilize Mirus Bio’s nucleic acid delivery platforms

As part of this collaboration, Organon has acquired an equity interest in HUYA, which identifies, licenses and develops Chinese drug candidates. Under the collaboration agreement, HUYA will support

Although the US biotech company will not release end of year results until February, the update reflected a rise in its sales forecast for 2006 and 2007. Pharmion

Tests evaluating Viprovex as a potential influenza infection treatment were conducted at Virion Systems, a Maryland biotechnology corporation. The company believes that preliminary results of Viprovex treatment of